Wuhan Healthgen Biotechnology (SHSE:688765) Tax Provision: ¥0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
21 GF Score
Price ¥38.50
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology Tax Provision?

Wuhan Healthgen Biotechnology SHSE:688765 -1.28% 21 Tax Provision is ¥0.00 Mil as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 21/100. The stock has 7 warning signs investors should review.

Wuhan Healthgen Biotechnology's tax provision for the three months ended in Mar. 2026 was ¥0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.00 Mil.

Wuhan Healthgen Biotechnology Tax Provision Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology Tax Provision Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688765
21GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ¥0.00 Mil mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a Tax Provision of ¥0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Wuhan Healthgen Biotechnology and its competitors.
Is Wuhan Healthgen Biotechnology's Tax Provision too high?
Wuhan Healthgen Biotechnology's current Tax Provision is ¥0.00 Mil. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Tax Provision compare to ZTS?
Wuhan Healthgen Biotechnology's Tax Provision of ¥0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Wuhan Healthgen Biotechnology and its competitors. Wuhan Healthgen Biotechnology's current Tax Provision is ¥0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Tax Provision of ¥0.00 Mil. The current Tax Provision is ¥0.00 Mil. Wuhan Healthgen Biotechnology's overall GF Score™ is 21/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Tax Provision is ¥0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
21GF Score

Get the complete analysis for SHSE:688765

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.50
Price